Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 871 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Approximately 1 Million of New Maternal Orphans Due to Cancer in... November 28, 2022 A College Senior vs. A Global Pandemic September 30, 2020 Experimental mRNA Vaccine Hints at Potential Against Glioblastoma June 11, 2024 Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously... June 16, 2026 Load more HOT NEWS Cancer target missed for 55,000 patients over 6 years Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary... 40 K9 Officers Line Up Outside Terminally Ill Girl’s House For... EMA Recommends Extension of Indications for Lorlatinib
